Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Guy

Showing results (21-30 of 60) with videos related to

Pageof 6
Sort By:
Vaccines|April 15, 2020
When Can One Vaccinate with a Live Vaccine after Wild-Type Dengue Infection?Bruno Guy, Eng Eong Ooi, Jose Ramos-Castañeda, et al.
Vaccine|June 25, 2008
Safety of flavivirus chimeric vaccines: answer to Ishikawa et al. [Vaccine 26 (22) (2008) 2772-2781]Bruno Guy, Farshad Guirakhoo, Michael Watson, et al.
Immunology Letters|December 9, 2004
Do Th1 or Th2 sequence motifs exist in proteins? Identification of amphipatic immunomodulatory domains in Helicobacter pylori catalaseBruno Guy, Tino Krell, Violette Sanchez, et al.
Vaccine|July 13, 2011
From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccineBruno Guy, Beatrice Barrere, Claire Malinowski, et al.
Vaccine|October 8, 2009
Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis virusesBruno Guy, Farshad Guirakhoo, Veronique Barban, et al.
Vaccine|November 3, 2009
Memory B and T cell responses induced by serotype 4 Streptococcus pneumoniae vaccines: longitudinal analysis comparing responses elicited by free polysaccharide, conjugate and carrierFlorence Deauvieau, Sebastien Dussurgey, Daniele Rossignol, et al.
Vaccine|September 9, 2017
Biodistribution and safety of a live attenuated tetravalent dengue vaccine in the cynomolgus monkeyGuillaume Ravel, Nathalie Mantel, Jeremy Silvano, et al.
The Journal of Infectious Diseases|December 15, 2010
Different innate signatures induced in human monocyte-derived dendritic cells by wild-type dengue 3 virus, attenuated but reactogenic dengue 3 vaccine virus, or attenuated nonreactogenic dengue 1-4 vaccine virus strainsClaire Balas, Audrey Kennel, Florence Deauvieau, et al.
The American Journal of Tropical Medicine and Hygiene|January 27, 2007
Innate immune responses in human dendritic cells upon infection by chimeric yellow-fever dengue vaccine serotypes 1-4Florence Deauvieau, Violette Sanchez, Claire Balas, et al.
The Journal of Infectious Diseases|July 16, 2016
Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2-16 Years in Asia and Latin AmericaGustavo Olivera-Botello, Laurent Coudeville, Karen Fanouillere, et al.
Pageof 6

Showing results (21-30 of 60) with videos related to

Sort By:
Pageof 6
Vaccines|April 15, 2020
When Can One Vaccinate with a Live Vaccine after Wild-Type Dengue Infection?Bruno Guy, Eng Eong Ooi, Jose Ramos-Castañeda, et al.
Vaccine|June 25, 2008
Safety of flavivirus chimeric vaccines: answer to Ishikawa et al. [Vaccine 26 (22) (2008) 2772-2781]Bruno Guy, Farshad Guirakhoo, Michael Watson, et al.
Immunology Letters|December 9, 2004
Do Th1 or Th2 sequence motifs exist in proteins? Identification of amphipatic immunomodulatory domains in Helicobacter pylori catalaseBruno Guy, Tino Krell, Violette Sanchez, et al.
Vaccine|July 13, 2011
From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccineBruno Guy, Beatrice Barrere, Claire Malinowski, et al.
Vaccine|October 8, 2009
Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis virusesBruno Guy, Farshad Guirakhoo, Veronique Barban, et al.
Vaccine|November 3, 2009
Memory B and T cell responses induced by serotype 4 Streptococcus pneumoniae vaccines: longitudinal analysis comparing responses elicited by free polysaccharide, conjugate and carrierFlorence Deauvieau, Sebastien Dussurgey, Daniele Rossignol, et al.
Vaccine|September 9, 2017
Biodistribution and safety of a live attenuated tetravalent dengue vaccine in the cynomolgus monkeyGuillaume Ravel, Nathalie Mantel, Jeremy Silvano, et al.
The Journal of Infectious Diseases|December 15, 2010
Different innate signatures induced in human monocyte-derived dendritic cells by wild-type dengue 3 virus, attenuated but reactogenic dengue 3 vaccine virus, or attenuated nonreactogenic dengue 1-4 vaccine virus strainsClaire Balas, Audrey Kennel, Florence Deauvieau, et al.
The American Journal of Tropical Medicine and Hygiene|January 27, 2007
Innate immune responses in human dendritic cells upon infection by chimeric yellow-fever dengue vaccine serotypes 1-4Florence Deauvieau, Violette Sanchez, Claire Balas, et al.
The Journal of Infectious Diseases|July 16, 2016
Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2-16 Years in Asia and Latin AmericaGustavo Olivera-Botello, Laurent Coudeville, Karen Fanouillere, et al.
Pageof 6